![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Fast Tracks Cellceutix’s Oral Mucositis Candidate
FDA Fast Tracks Cellceutix’s Oral Mucositis Candidate
December 3, 2015
Cellceutix has won FDA fast track designation for its Brilacidin-OM, an oral rinse formulation for preventing oral mucositis, a side effect associated with certain cancer treatments.
The candidate is currently in Phase 2 trials in patients undergoing chemoradiation for the treatment of head and neck cancer.
Upcoming Events
-
21Oct